Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes

Medicine

Volumn 79, Issue 4, 2000, Pages 250-260

  Patterson, Thomas F ^a,f   Kirkpatrick, William R ^a   White, Mary ^b   Hiemenz, John W ^c   Wingard, John R ^d   Dupont, Bertrand ^g   Rinaldi, Michael G ^a,f   Stevens, David A ^e   Graybill, John R ^a,f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^f SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^g INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; COMORBIDITY; DIAGNOSTIC APPROACH ROUTE; DISEASE PREDISPOSITION; DRUG FORMULATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFANT, NEWBORN; ITRACONAZOLE; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 0033856265     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200007000-00006     Document Type: Article

References (69)

1. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers
2. Invasive pulmonary aspergillosis. MRI, CT, and plain radiographic findings and their contribution for early diagnosis
3. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
4. The pharmacokinetic rationale behind intravenous itraconazole (abstract A75)
5. In vitro antifungal activity of L743872 against a variety of moulds (abstract F33)
6. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis
7. The efficacy and tolerability of UK109, 496 (Voriconazole) in the treatment of invasive aspergillosis (abstract P552)
8. Antifungal and surgical treatment of invasive aspergillosis: Review of 2, 121 published cases
9. Treatment of invasive aspergillosis with itraconazole
10. Itraconazole resistance in Aspergillus fumigatus
11. Therapeutic outcome in invasive aspergillosis
12. Invasive aspergillosis
13. Itraconazole therapy in aspergillosis: Study in 49 patients
14. UK-109-496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in chronic invasive aspergillosis (abstract F81)
15. Detection and identification of fungal pathogens in blood by using molecular probes
16. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
17. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
18. Amphotericin B: 30 years of clinical experience
19. Aspergillus brain abscess after liver transplantation with long-term survival. A case report
20. Combination therapy in experimental invasive aspergillosis
21. Antifungal agents: Chemotherapeutic targets and immunologic strategies
22. Lipid formulations for amphotericin B: Does the emperor need new clothes?
23. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
24. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: Historical control comparison with amphotericin B
25. Lipid formulations of amphotericin B: Recent progress and future directions
26. The use of respiratory-tract culture in the diagnosis of invasive aspergillosis
27. Effect of cyclodextrin on the pharmacology of antifungal oral azoles
28. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature
29. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants
30. Invasive pulmonary aspergillosis in acute leukemia: Characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis
31. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management
32. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus cultures after liver transplantation
33. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infection
34. Sch 59884, the intravenous prodrug of the antifungal triazole Sch 56592 (abstract 1933)
35. Fungal pulmonary infections after bone marrow transplantation: Evaluation with radiography and CT
36. Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome
37. Impact of previous aspergillosis on the outcome of bone marrow transplantation
38. Localization of aspergillosis to the central nervous system among patients with acute leukemia: Report of 14 cases
39. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: A 9-year study
40. Invasive aspergillosis in transplant recipients
41. Hospital epidemiologic surveillance for invasive aspergillosis: Patient demographics and the utility of antigen detection
42. Efficacy of SCH 56592 in a rabbit model of invasive aspergillosis (abstract F98)
43. Aspergillus antigen detection in the diagnosis of invasive aspergillosis
44. Systemic availability of itraconazole in lung transplantation
45. Approaches to the therapy of invasive mycoses - The role of amphotericin B
46. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY 303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
47. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: Meeting report
48. In vitro activity of antifungal agent LY303366 against Candida species, other yeasts, and Aspergillus species (abstract F45)
49. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation
50. Treatment of cerebral Aspergillosis with itraconazole: Do high doses improve the prognosis?
51. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis
52. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism
53. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia
54. Successful treatment of cerebral aspergillosis with a novel triazole (Voriconazole) in a patient with acute leukemia
55. Current and emerging azole anti-fungal agents
56. Detection of Aspergillus fumigatus by polymerase chain reaction
57. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria
58. Itraconazole in cyclodextrin solution
59. The detection of Aspergillus spp. by the polymerase chain reaction and its evaluation in bronchoalveolar lavage fluid
60. Panfungal PCR assay for detection of fungal infection in human blood specimens
61. Treatment of cryptococcal meningitis associated with the acquired inmunodeficiency syndrome
62. Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples
63. Current trends in the detection of antigenaemia, metabolites and cell wail markers for the diagnosis and therapeutic monitoring of fungal infections
64. Sandwich enzyme-linked immunosorbent assay compared with pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients
65. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
66. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
67. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
68. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis